Bart Neyns
机构: Diensthoofd, Medische Oncologie, Universitair Ziekenhuis Brussel
每年引用次数
引用次数
引用: 33,394
H-指数: 72
I10-指数 : 206
出版物: 545
Study of clinical determinants in prescribing capecitabine in patients receiving first-line therapy for metastatic colorectal cancer under 'real practice' conditions in Belgium and Luxemburg
Bart Neyns , A. Bols , E.j.r. Joossens , M. De Man
Annals of Oncology 18 78 -78
2007
Determination of EGFR, Her2/neu, PTEN, and p53 protein expression and gene status by immunohistochemistry and fluorescence in situ hybridization in high-grade glioma
Bart Neyns , Jan Sadones , Theo Strauven , Jacques De Greve
Neuro-oncology 8 325 -325
2006
Analysis of the efficacy and tolerability of gefitinib ('Iressa', ZD1839) in previously treated patients with non-small-cell lung cancer enrolled in the 'Iressa' Expanded Access Program
Bart Neyns , Jacques De Greve , Denis Schallier , Erika Sermijn
2003
High total metabolic tumor volume on 18F-FDG-PET/CT correlates with lack of immune response in advanced melanoma patients treated with pembrolizumab.
Hendrik Everaert , Lode Goethals , Julia Katharina Schwarze , Gil Awada
Imaging Immunity: from Nanoscale to Macroscale
2020
Electroporation efficiency of human dendritic cells is affected by granulocyte contamination in elutriated monocytes.
Bart Neyns , Aude Bonehill , An Van Nuffel , Daphné Benteyn
11th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology
2010
A phase I clinical trial on intratumoral and intracavitary administration of ipilimumab and nivolumab in patients with recurrent glioblastoma: Brussel Poster presentation on Glitipni-study at ASCO Annual Meeting 2020; May 29 - June 2, 2020; virtual
Bart Neyns , Johnny Duerinck , Hendrik Everaert , Alex Michotte
2020
The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
Bart Neyns , Bart Ilsen , Lore Decoster , Hendrik Everaert
Clinical Lung Cancer
13
2021
Choriocapillaris Assessment In Patients Under Mek-Inhibitor Therapy For Cutaneous Melanoma: An Optical Coherence Tomography Angiography Study.
Bart Neyns , Marcel Ten Tusscher , Gil Awada , Jorgos Socrates Koulalis
Seminars in Ophthalmology 1 -7
2021
A versatile cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
Marleen Keyaerts , Bart Neyns , Karine Breckpot , Fumihiro Fujiki
BIS meeting
2017
Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization.
Steven De Vleeschouwer , Steven De Vleeschouwer , Olivier De Wever , Bart Neyns
Nature Neuroscience 24 ( 4) 595 -610
167
2021
A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R/K/L Mutant Melanoma (TraMel-WT).
Bart Neyns , Julia Katharina Schwarze , Gil Awada , Giuseppe Fasolino
Cancers 13 ( 9) 2010
2021
Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
Marleen Keyaerts , Bart Neyns , Gil Awada , Sim Vermeulen
Current Oncology 28 ( 3) 1630 -1640
2021
Sarcoid-like reaction in a BRAF V600E-mutated metastatic melanoma patient during treatment with BRAF/MEK-targeted therapy.
Bart Neyns , Sandrine Aspeslagh , Julia Katharina Schwarze , Gil Awada
Melanoma Research 31 ( 3) 272 -276
2021
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).
Pier Francesco Ferrucci , Roberta Depenni , Bart Neyns , Ivana Krajsová
Cancers 13 ( 10) 2466
2021
The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
Judith M Versluis , Anne M Hendriks , Alison M Weppler , Lauren J Brown
European Journal of Cancer 151 72 -83
2021
S2-106 Talimogene laherparepvec (T-VEC)-induced tumor oncolysate as a source of tumor antigens and maturation factors for blood-isolated myeloid dendritic cells
Bart Neyns , Karine Breckpot , Joeri Aerts , Sandra Tuyaerts
18th annual meeting of the association for Cancer Immunotherapy
2021
C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting.
Bart Neyns , Sandrine Aspeslagh , Valérie Vandersleyen , Julia Katharina Schwarze
Melanoma Research
2021
Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.
Michael J Overman , Sara Lonardi , Francesco Leone , Raymond S McDermott
Journal of Clinical Oncology 35 519 -519
40
2017
Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
Michael J. Overman , Sara Lonardi , Ka Yeung Mark Wong , Heinz-Josef Lenz
Journal of Clinical Oncology 36 ( 8) 773 -779
623
2018
Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).
Elisa A. Rozeman , Yanina Jansen , MarnixMarnix Heimen Geukes Foppen , Max Schreuer
Journal of Clinical Oncology 34
2016